Development and Validation of UV-Visible Spectrophotometric Baseline Manipulation Method for Simultaneous Quantitation of Tenofovir Disoproxil Fumarate and Emtricitabine in Pharmaceutical Dosage Form

Development and Validation of UV-Visible Spectrophotometric Baseline Manipulation Method for Simultaneous Quantitation of Tenofovir Disoproxil Fumarate and Emtricitabine in Pharmaceutical Dosage Form

A simple, economical, precise, and accurate new UV-visible spectrophotometric baseline manipulation method for simultaneous determination of tenofovir disoproxil fumarate (TE) and emtricitabine (EM) in combined tablet dosage form has been developed. The method is based on baseline manipulation (dif...

Full description

Bibliographic Details
Main Authors:	Vishnu P. Choudhari, Sanket R. Parekar, Subhash G. Chate, Pradeep D. Bharande, Rajiv R. Singh, Bhanudas S. Kuchekar
Format:	Article
Language:	English
Published:	Hindawi Limited 2013-01-01
Series:	Journal of Spectroscopy
Online Access:	http://dx.doi.org/10.1155/2013/146580

Similar Items

New simple spectrophotometric method for determination of the antiviral mixture of emtricitabine and tenofovir disoproxil fumarate
by: Heba K. Ashour, et al.
Published: (2017-05-01)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
by: Wissam K. Kabbara, et al.
Published: (2015-09-01)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
by: Lucia Taramasso, et al.
Published: (2019-01-01)

Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance
by: Yu-Yu Hsiao, et al.
Published: (2021-08-01)

Simple Spectrophotometric Methods for Determination of Tenofovir Fumarate and Emtricitabine in Bulk Powder and in Tablets
by: Mohammad H. AbdelHay, et al.
Published: (2013-01-01)

Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
by: Nicholas T Funderburg, et al.
Published: (2013-01-01)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures.
by: Priya Srinivasan, et al.
Published: (2016-01-01)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
by: Chanie Wassner PharmD, BCCCP, BCIDP, et al.
Published: (2020-04-01)

Liquid chromatography metabolite profiling of tenofovir disoproxil fumarate
by: Kokil Sachin, et al.
Published: (2009-01-01)

The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01)

Iatrogenic Adrenal Insufficiency Secondary to Combination Therapy with Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Interlaminar Triamcinolone Injection in an AIDS Patient
by: Chanie Wassner PharmD, BCCCP, et al.
Published: (2017-11-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya
by: Owino F, et al.
Published: (2013-11-01)

Effects of Hydrochlorothiazide on Tenofovir Disoproxil Fumarate-Induced Nephrotoxicity in Rats
by: Iman G.Al-Rakhat, et al.
Published: (2019-12-01)

Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
by: J Jones, et al.
Published: (2010-05-01)

Formulation, development and assessment of tenofovir disoproxil fumarate-loaded pellets
by: Dube, Tawanda
Published: (2015)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
by: Andrew Hill, et al.
Published: (2018-04-01)

Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes
by: Kubra Kurt, et al.
Published: (2016-06-01)

Latest progress in treatment of chronic hepatitis B with tenofovir disoproxil fumarate
by: ZHANG Yue
Published: (2015-04-01)

Safety of atazanavir/ritonavir with tenofovir disoproxil fumarate in HIV-infected adolescents
by: T. Bunupuradah, et al.
Published: (2014-04-01)

Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review
by: Mark J. Naccarato BSc Pharm, et al.
Published: (2018-01-01)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
by: Linn Hermansson, et al.
Published: (2019-01-01)

Review: Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B
by: Andrés Duarte-Rojo, et al.
Published: (2010-03-01)

Stress Studies of Tenofovir Disoproxil Fumarate by HPTLC in Bulk Drug and Pharmaceutical Formulation
by: Shweta Havele, et al.
Published: (2012-01-01)

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate
by: Kate Braithwaite, et al.
Published: (2021-08-01)

Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate
by: Tim R. Cressey, et al.
Published: (2020-08-01)

Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B
by: Daiki Aomura, et al.
Published: (2020-10-01)

Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
by: Ping Zhang, et al.
Published: (2018-08-01)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
by: Squillace N, et al.
Published: (2020-12-01)

Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
by: Calvin Q Pan, et al.
Published: (2021-01-01)

Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
by: Kathleen Listiak Vincent, et al.
Published: (2018-01-01)

Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
by: Karin Neukam, et al.
Published: (2016-01-01)

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
by: Nicola Squillace, et al.
Published: (2017-01-01)

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors
by: Pontrelli Giuseppe, et al.
Published: (2012-01-01)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Setting
by: The Staff
Published: (2014-01-01)

Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
by: Calvin Q Pan, et al.
Published: (2014-01-01)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Setting.
Published: (2014-01-01)